ASBP Stock Jumps 21% On Buyback Offer – Retail Believes Every Dip’s A Buying Opportunity

• Aspire Biopharma is expanding beyond its core biotech business and recently announced a $30 million all-cash acquisition of Dura Control Systems, a global automotive supplier.
• The firm secured a $22.5 million credit facility for the acquisition and added that it does not expect to raise additional equity.
• Aspire Biopharma had implemented a 1-for-40 reverse stock split on Jan. 16, 2026.

Shares of Aspire Biopharma Holdings (ASBP) surged more than 21% on Monday, logging their biggest jump in over a month as a fresh $5 million buyback plan sparked renewed investor interest.

Aprire Biopharma’s board approved a share repurchase program of up to $5 million, to be funded from existing cash and executed over time through open-market purchases or private transactions.

“Aspire’s strengthened financial position provides us with significant flexibility in executing our capital allocation strategy. The Board's authorization of a $5 million share repurchase program further supports our commitment to returning value to shareholders,” said CEO Kraig Higginson.

Move Beyond Biotech

Aspire Biopharma is expanding beyond its core biotech business with a planned $30 million all-cash acquisition of Dura Control Systems (DCS), a global automotive supplier. DCS generates over $200 million in annual revenue and more than $20 million in earnings, with a broad portfolio of parts and patents used by major automakers.

To support the acquisition, it recently secured a $22.5 million credit facility and added that it does not expect to raise additional equity.

Separately, Aspire is growing its consumer segment through its Buzz Bomb unit, which recently partnered with Interwest Brokerage to expand retail distribution. The product is a sublingual caffeine powder that delivers a quick energy boost without the need for traditional drinks like coffee or energy beverages.

How Did Retail Traders React?

Retail sentiment on Stocktwits for ASBP remained ‘bullish’ over the past 24 hours, amid ‘extremely high’ message volumes.

One user said every dip was a buying opportunity as the stock climbs toward $2. It is currently trading around $0.3.

However, another user said the $5 million buyback looks more like a “distraction” than a “deal.”

Aspire Biopharma implemented a 1-for-40 reverse stock split on Jan. 16, 2026.

Read also: POET Stock On Track To Record Biggest Single-Day Fall After Disclosing Order Cancellation From Celestial AI – Here’s What Happened

For updates and corrections, email newsroom[at]stocktwits[dot]com.